Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 NorthStar Medical Radioisotopes Enter Strategic Supply Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

NorthStar Medical Radioisotopes Enter Strategic Supply Pact

NorthStar to provide Alpha-9 with its non-carrier added Actinium-225 (Ac-225) for use in development and clinical programs.

By: Anthony Vecchione

NorthStar Medical Radioisotopes, LLC, a company involved in the development, production and commercialization of radiopharmaceuticals, and Alpha-9 Oncology Inc., a clinical stage biotechnology company developing highly targeted radiopharmaceuticals to treat a range of cancers, entered into a long-term strategic supply agreement for NorthStar to provide Alpha-9 with its non-carrier added Actinium-225 (Ac-225) for use in its development and clinical programs.

“NorthStar, using its advanced electron accelerator technology, is on schedule to be one of the first commercial-scale producers of n.c.a. Ac-225,” said Frank Scholz, CEO of NorthStar Medical Radioisotopes. “The n.c.a. Ac-225 we produce is free of long-lived radioactive contaminants and byproducts associated with other production methods – contaminants that pose regulatory and waste management challenges for pharmaceutical companies, hospitals, and health systems.”

Scholz added: “NorthStar’s advanced technology and expertise in isotope production will accelerate Alpha-9’s ability to advance a number of innovative, specialized radiopharmaceuticals to benefit patients with solid tumors and a variety of blood cancers while minimizing unwanted off-target effects.”

David Hirsch, CEO of Alpha-9 Oncology said, “The Alpha-9 team is well positioned to progress multiple targets into the clinic. Robust supply of high-quality Ac-225 will help us advance a new generation of highly effective radiopharmaceuticals with improved tumor uptake and limited off-target exposure. We look forward to working with NorthStar and bringing our molecules to patients.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics